Immuneering (IMRX) Assets Average (2021 - 2026)
Immuneering (IMRX) posted quarterly Assets Average of $223.4 million for Q1 2026, up 332.12% year-over-year from $51.7 million in Q1 2025, and down 5.55% quarter-over-quarter from $236.5 million in Q4 2025.
Immuneering (IMRX) Assets Average (2021 - 2026) Analysis & Trends
Immuneering's Assets Average history runs 6 years deep, the most recent figure standing at $223.4 million for Q1 2026.
- In Q1 2026, Assets Average rose 332.12% year-over-year to $223.4 million; the TTM figure through Mar 2026 stood at $223.4 million (up 332.12% YoY), while the FY2025 annual figure was $142.3 million, up 83.32% from the prior year.
- Assets Average for Q1 2026 stood at $223.4 million, down from $236.5 million in the prior quarter.
- The five-year high for Assets Average was $236.5 million in Q4 2025, with the low at $45.4 million in Q2 2025.
- The 5-year median for Assets Average is $116.3 million (2023), against an average of $120.0 million.
- The sharpest annual moves came in 2025 and 2026: Assets Average slumped 45.74% in 2025, then jumped 332.12% in 2026.
- Immuneering's Assets Average stood at $128.0 million in 2022, then slipped by 15.46% to $108.2 million in 2023, then tumbled by 43.98% to $60.6 million in 2024, then surged by 290.07% to $236.5 million in 2025, then slipped by 5.55% to $223.4 million in 2026.
- Business Quant data shows IMRX's Assets Average at $223.4 million in Q1 2026, $236.5 million in Q4 2025, and $140.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 208.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 208.43 Mn |
| Mar 31, 2026 | 223.40 Mn |
| Dec 31, 2025 | 236.52 Mn |
| Sep 30, 2025 | 140.56 Mn |
| Jun 30, 2025 | 45.37 Mn |
| Mar 31, 2025 | 51.70 Mn |
| Dec 31, 2024 | 60.64 Mn |
| Sep 30, 2024 | 72.82 Mn |
| Jun 30, 2024 | 82.54 Mn |
| Mar 31, 2024 | 95.28 Mn |
| Dec 31, 2023 | 108.23 Mn |
| Sep 30, 2023 | 119.39 Mn |
| Jun 30, 2023 | 116.30 Mn |
| Mar 31, 2023 | 115.03 Mn |
| Dec 31, 2022 | 128.03 Mn |
| Sep 30, 2022 | 137.87 Mn |
| Jun 30, 2022 | 147.25 Mn |
| Mar 31, 2022 | 159.58 Mn |
| Dec 31, 2021 | 165.37 Mn |
| Sep 30, 2021 | 108.54 Mn |